MedTrace Logo

Study to Evaluate the Safety of Rotarix™ in Chinese Children

NCT01086436 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-05-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy children aged 2 to 6 years in China.

Conditions

  • Infections, Rotavirus

Interventions

BIOLOGICAL

Rotarix ™

Oral, single dose

BIOLOGICAL

Placebo

Oral, single dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-13
Primary Completion
2010-04-16
Completion
2010-04-16

Countries

  • China

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086436 on ClinicalTrials.gov